Skip to content

Efficacy Of Antenatal Maternal Supplementation With GOS/Inulin Prebiotics On Atopic Dermatitis Prevalence In High-Risk One-Year-Old Children

A Multicenter Clinical Trial To Assess The Efficacy Of Antenatal Maternal Supplementation With GOS/Inulin Prebiotics On Atopic Dermatitis Prevalence In High-Risk One-Year-Old Children.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03183440
Acronym
PREGRALL
Enrollment
376
Registered
2017-06-12
Start date
2018-02-13
Completion date
2023-08-31
Last updated
2021-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dermatitis, Atopic

Keywords

Atopic dermatitis, Prevention, Prebiotics, Pregnancy

Brief summary

Allergies are increasing worldwide affecting 30-40% of the population. Among this, Atopic Dermatitis (AD) is the earliest and the most common manifestation of allergic diseases (prevalence 20%). Recent studies have shown that allergies were associated with a disruption of the gut microbial 'balance' suggesting that the use of nutritional intervention very early in life may restore an optimal pattern of microflora aiming at improving the host's health. So far, most human intervention studies have mainly focused on improving postnatal infant colonization. Our study will test the hypothesis that a maternal antenatal prebiotics (GOS/inulin) supplementation may be superior to placebo for AD prevention in high-risk children.

Detailed description

Study design : Inclusion visit at 20 weeks of gestation : * randomization * start of supplementation (GOS/inulin or placebo) Phone call at 24 weeks of gestation : * checking tolerance * checking observance 32 weeks of gestation visit : * replenishment of prebiotics * collect of AE Day 1 : assessment of the Transepidermal Waterlos evaluated by a TEWAMETER Delivery/per partum Visit At M3 : The national recommendations for the dietary diversification of the child will be transmitted to the patients At M6 : evaluation of AD prevalence by parents At M12 : Pediatric dermatology consultation * clinical exam of child * the SCORAD * the POEM questionnaire * prevalence of AD * skin prick tests * FDQLI score * assessment of the Transepidermal Waterlos evaluated by a TEWAMETER * prevalence of food allergies

Interventions

DIETARY_SUPPLEMENTPREBIOTICS

women will daily take a mixture of Galacto-Oligo-Saccharide/inulin (ratio 9:1) from inclusion to delivery

OTHERPLACEBO

women will daily take placebo (maltodextrin) from inclusion to delivery

Sponsors

Nantes University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* pregnant women with an eutocic pregnancy before 20 weeks of gestation * women with personal history of atopy diagnosed by a healthcare Professional * Women accepting a complete avoidance of dietary supplements containing prebiotics or probiotics during study supplementation * women accepting dermato-pediatric follow-up during the first year of life of the new-born (Phone calls at 24 weeks of gestation and 6 months of child and a consultation at 12 months of age) * non Tobacco user women * women over 18 years * women without history of severe gestational diabetes

Exclusion criteria

* women not giving up on intake of dietary supplements containing prebiotics or probiotics during study supplementation * women refusing dermato-pediatric follow-up during the first year of the newborn * ongoing allergy and/or intolerance to cow's milk proteins * term \>21 weeks of gestation

Design outcomes

Primary

MeasureTime frameDescription
atopic dermatitis prevalence at M12at 12 months of ageprevalence will be evaluated according to UK party working group criteria

Secondary

MeasureTime frameDescription
atopic dermatitis severityat 12 months of ageevaluated by the SCORAD (Scoring Atopic Dermatitis)
Quality of life of the child and his/her familyat 12 months of ageevaluated by the FDQLI score (Family Dermatitis Quality of life Index)
Tolerance of the prebiotics in mothersfrom inclusion to deliveryevaluated by a questionnaire on digestive status (bloating, stomach aches, diarrhea, flatulences,...)
atopic dermatitis prevalence at M6at 6 months of ageprevalence will be evaluated by a phone questionnaire (ISAAC questionnaire)
assessment of the Transepidermal Waterlosat J1 and at 12 months of ageevaluated by a TEWAMETER(R)
food allergies prevalence at M12at 12 months of agePrevalence will be evaluated by recording food allergies diagnosed by a physician
sensitization with the major allergensat 12 months of ageskin prick tests

Countries

France

Contacts

Primary ContactSebastien BARBAROT, Dr
sebastien.barbarot@chu-nantes.fr(0)240084086
Backup ContactHélène AUBERT, Dr
helene.aubert@chu-nantes.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026